Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) is currently trading at 213.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Jagsonpal Pharmaceuticals Limited is an India-centric pharmaceutical company focused on branded generics, sub-chronic therapies and a growing hospital and consumer wellness business through product marketing, outsourced manufacturing and strategic acquisitions to expand therapeutic reach and distribution footprint. The company reported FY26 revenue of INR 287 crore and strong operational improvement between FY22–FY26: operating EBITDA grew at a 24.9% CAGR and operational PAT grew at a 23.9% CAGR, highlighting substantial margin expansion and free-cash-flow generation that enabled disciplined acquisitions. Recent inorganic moves are transformative: Aequitas Healthcare brought 1,000+ hospital access and institutional channels while the wellness portfolio acquisition immediately added ~INR 24.6 crore revenue and high 78% gross margins, improving cross-sell opportunities and doctor reach in six states. Jagsonpal maintains a strong cash position and liquidity — Q1FY27 cash reported around INR 170 crore — and uses a structured acquisition payment profile (≈50% deferred for Group Pharma deal) to preserve flexibility and align consideration with future performance. The company’s strategic ambition, Mission 2028 to reach INR 500 crore, is explicit and backed by a repeatable M&A playbook plus field-force productivity targets and an asset-light operating model aimed at sustained margin expansion and double-digit EBITDA gains.

Over the past 52 weeks, Jagsonpal Pharmaceuticals Ltd has traded between a low of ₹154.90 and a high of ₹264.65. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Jagsonpal Pharmaceuticals Ltd has a market capitalization of approximately 1,396.32. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Jagsonpal Pharmaceuticals Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 30.71 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 1,396.32 Cr, Jagsonpal Pharmaceuticals Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Jagsonpal Pharmaceuticals Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Jagsonpal Pharmaceuticals Ltd is 30.71. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Jagsonpal has signed an agreement to acquire an 85% equity stake in Aequitas Healthcare Private Limited for ₹20.8 crore in cash.

The board of Jagsonpal Pharmaceuticals has approved a buyback price of ₹250 per equity share through a tender offer.

The board of Jagsonpal Pharmaceuticals has approved a buyback of up to 16 lakh shares at a price of ₹250 per share, with a total maximum value of ₹40 crore. The buyback will be conducted through a tender offer.